Tag: gene-editing

CRISPR Therapeutics AG (CRSP) is rated STRONG SELL as its valuation already prices in a much faster commercial ramp than current revenue and cash generation support. With heavy cash burn and negative operating cash flow, the stock leaves little margin for error despite a strong balance sheet.

Read note